Evaluating <scp>miRNA</scp> Sequencing and Integrative Proteomics for Identifying Plasma <scp>miRNAs</scp> as Potential Pharmacodynamic Biomarkers of <scp>IFNβ</scp> ‐1a Biologics
Year: 2025
Type: article
Language: en
Topic: MicroRNA in disease regulation
Authors and affiliations:
raw_author_name: Mai Mehanna
raw_affiliation_strings: Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research U.S. Food and Drug Administration  Silver Spring Maryland USA
raw_author_name: Lakshmi Manasa Chekka
raw_affiliation_strings: Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research U.S. Food and Drug Administration  Silver Spring Maryland USA
raw_author_name: Barry A. Rosenzweig
raw_affiliation_strings: Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research U.S. Food and Drug Administration  Silver Spring Maryland USA
raw_author_name: Deepti P. Samarth
raw_affiliation_strings: Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research U.S. Food and Drug Administration  Silver Spring Maryland USA
raw_author_name: Esraa G. Mohamed
raw_affiliation_strings: Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research U.S. Food and Drug Administration  Silver Spring Maryland USA
raw_author_name: Isaac Raplee
raw_affiliation_strings: Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research U.S. Food and Drug Administration  Silver Spring Maryland USA
raw_author_name: Catherine Sullenberger
raw_affiliation_strings: Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research U.S. Food and Drug Administration  Silver Spring Maryland USA
raw_author_name: Erica Decker
raw_affiliation_strings: Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research U.S. Food and Drug Administration  Silver Spring Maryland USA
raw_author_name: Sarah J. Schrieber
raw_affiliation_strings: Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation and Research U.S. Food and Drug Administration  Silver Spring Maryland USA
raw_author_name: Yow‐Ming Wang
raw_affiliation_strings: Therapeutic Biologics Program, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research U.S. Food and Drug Administration  Silver Spring Maryland USA
raw_author_name: Jeffry Florian
raw_affiliation_strings: Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research U.S. Food and Drug Administration  Silver Spring Maryland USA
raw_author_name: Paula L. Hyland
raw_affiliation_strings: Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research U.S. Food and Drug Administration  Silver Spring Maryland USA